Background This study evaluated the efficacy and safety of anlotinib combined with
programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer …

Aims Combination of anti-angiogenesis therapy and immunotherapy has showed synergistic
effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to …

Objectives Treatments for advanced small‐cell lung cancer (SCLC) patients who are
resistant to first‐line chemotherapy are limited. Given that antiangiogenic agents and …

Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …

Background Pre-clinical and clinical evidences support that simultaneous blockade of
programmed death-1 (PD-1) and vascular endothelial growth factor receptor (VEGFR) can …

Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …

Background Anlotinib showed significant survival benefits in advanced non‐small cell lung
cancer (NSCLC) patients as a third‐or further‐line treatment in the ALTER0303 trial. We …

Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …

Objectives Combined therapy should be invested for those patients who are refractory to first-
line therapy. Anti-angiogenic agents could enhance tumor immunity response. We designed …

Background The aim of this study was to investigate the efficacy and safety of anlotinib for
patients with advanced non-small cell lung cancer (NSCLC) who progressed after standard …